Chemotherapy:Albumin-bound paclitaxel、Gemcitabine
Phase 2Small molecule
Chemotherapy:Albumin-bound paclitaxel、Gemcitabine is one of 49 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
94 competitors in Pancreatic Ductal Adenocarcinoma
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Eloxatin
TevaPhase 3
Camptosar
PfizerPhase 3
Adrucil
EElorac, Inc.
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
5-Fluorouracil
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Folinic Acid
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Ductal Adenocarcinoma1 trial
PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)
Not yet recruiting·SSecond Affiliated Hospital of Soochow University·Phase 1/2·NCT06345599·66 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details